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Background: Aptamers have emerged as excellent molecular probes for cancer diagnosis and therapy. The aim of
the current study was to determine the feasibility of using DNA aptamer cy-apt 20 developed by live cell-SELEX for
detecting and targeting gastric cancer.
Methods: The specificity, sensitivity and biostability of cy-apt 20 in detecting gastric cancer were assessed by binding
assay, cell fluorescence imaging, and in vivo tumor imaging in animal model in comparison with non-gastric cancers.
Results: Flow cytometric analysis showed that cy-apt 20 had higher than 78% of maximal binding rate to gastric cancer
cells, much higher than that of non-gastric cancer cells. Cell fluorescence imaging and in vivo tumor imaging showed
that the targeting recognition could be visualized by using minimal dose of fluorochrome labeled cy-apt 20. Meanwhile,
strong fluorescence signals were detected and lasted for a period of time longer than 50 min in vitro and 240 min in vivo.
The fluorescence intensities of gastric cancer were about seven folds in vitro and five folds of that of non-gastric cancers
in vivo.
Conclusion: Our study demonstrated that cy-apt 20 was an excellent molecular probe with high specificity and sensitivity
and a certain degree of biostability for molecular recognition and targeting therapy of gastric cancer.
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Disease biomarkers are widely used in medicine, but
very few biomarkers are available for the diagnosis and
targeting therapy of gastric cancer so far [1,2]. Gastric
cancer is a highly aggressive malignancy often diagnosed
at an advanced stage [3]. Despite the decline in inci-
dence and the major improvements in diagnosis and
treatment, it remains the fourth commonest malignancy
and the second leading cause of cancer death worldwide
[3-5]. The carcinogenesis and progression of gastric can-
cer are determined by multi factors including Helicobacter
pylori infection, activation of oncogenic pathways and epi-
genetic elements [6-8]. Genes and molecules participating
in the proliferation, invasion, and metastasis of gastric
cancer, such as growth factors and their receptors, cell-* Correspondence: njmuyah@126.com
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unless otherwise stated.cycle regulators, cell-adhesion molecules and matrix-
degrading enzymes, etc. are all considered as important
determiners of prognosis [6-9]. It is desirable to identify
useful biomarkers from these factors for diagnosing, strati-
fying, targeting gastric cancer and, ultimately, improve the
survival of patients.
In the past two decades, great effort was made in search
of reliable biomarkers to revolutionize the diagnosis and
treatment of gastric cancer. By employing genomic, prote-
omic and metabolomic approaches, almost all genes and
molecules participating in cancer growth, invasion and me-
tastasis have been investigated as potential gastric cancer
biomarker. However, few of these initially promising bio-
markers have been validated for clinical use [1,2,7,8,10,11].
The main challenge in identifying reliable biomarkers is
the individual genetic variation and tumor heterogeneity,
many aspects of which remain unknown yet [6-8,11].
Other challenges include: the gene expression and protein
products depend much on the cross talk of cancer cells,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Evolution of gastric carcinoma cell-specific aptamer
cy-apt 20 by live cell-SELEX. Human gastric carcinoma AGS cells
were used as target cell for positive selections and human normal
gastric epithelial GES-1 cells as negative cell for counter selections.
The selection procedure was monitored by electrophoresis and flow
cytometry analyses. Selected DNA aptamers were labled with FITC
and their binding affinity to AGS cells were analyzed using flow
cytometry. Lib to AGS cells and each identified ssDNA sequence to
GES-1, HepG2 and SW620 cells were used as controls. The concentration
of these FITC-labeled ssDNA used was 400 nM, and results were
presented as mean ± standard error. (A) Ten ssDNA sequences with
high binding ability to AGS were identified from the final pool. (B) Four
of these ssDNA sequences were found have binding rates more than
60% to AGS cells, but only aptamer cy-apt 20 (arrow notified) have less
than 30% binding affinity to non-gastric carcinoma HepG2 and SW620
cells. FITC: fluorescein isothiocyanate. Lib: FITC-labeled unselected library
ssDNA. Apt or cy-apt: named identified ssDNA sequence. HepG2: human
hepatocellular carcinoma cell. SW620: human colon carcinoma cell.
Cao et al. BMC Cancer 2014, 14:699 Page 2 of 9
http://www.biomedcentral.com/1471-2407/14/699the genomic, proteomic and metabolomic approaches are
often too complex and expensive to be applied in clinic at
present time and biomarkers generated by such strategies
are out of context of cancer cells [11-13].
Recently, a new class of molecules termed aptamer has
emerged as excellent molecular probes for cancer diag-
nosis and targeting therapy [14,15]. Aptamers are single-
stranded DNA (ssDNA) or RNA typically generated by
an iterative screening process termed Systemic Evolution
of Ligands by Exponential Enrichment (SELEX) [16].
The SELEX procedure involves progressive purification
from a combinatorial library of nucleic acid ligands with
a high affinity for a particular target by repeated rounds
of partitioning and amplification [17]. In comparison
with other molecular recognition elements, aptamers have
the ability to bind specifically to a wide variety of targets
ranging from small organic molecules to proteins [14,15].
The basis for target recognition is the tertiary structures
formed by the single-stranded oligonucleotides [18]. In
addition, aptamers possess numerous advantageous char-
acteristics, including small size, lack of immunogenicity,
easy and reproducible synthesis, high binding affinity and
molecular specificity, fast tissue penetration and low tox-
icity, tenability in binding affinity, and long-term stability
[14,15]. To generate cancer specific aptamers in context
of cancer cells, an approach termed whole live cell based
SELEX (live cell-SELEX) has been developed [19]. Accu-
mulating evidences demonstrated that the live cell-SELEX
is simple, fast, straightforward, reproducible, and most im-
portantly, effective even when there is only a minor differ-
ence between a cancerous cell and an untransformed cell
of the same tissue type [14,15,20,21]. Thus far, a group of
cancer specific aptamers were generated by using live cell-
SELEX, some of them have been successfully used for can-
cer detection and targeting therapy [20-31].
We have developed a gastric cancer specific DNA apta-
mer cy-apt 20 by employing live cell-SELEX. A series of
experiments confirmed that, aptamer cy-apt 20 had higher
than 70% of binding rate to gastric cancer cells and less
than 30% of binding affinity to non-gastric cancer cells
(unpublished data, see Figure 1A and B). The results indi-
cated that the aptamer cy-apt 20 has great potential to be
used for the management of gastric cancer. The aim of
the current study was to determine the feasibility of using
cy-apt 20 as a molecular probe for detecting and targeting
gastric cancer.
Methods
Cell lines and cell culture
Human normal gastric epithelial cell line GES-1, gastric
carcinoma cell line AGS, liver hepatoma cell line HepG2
and colon carcinoma cell line SW620 were obtained from
American Type Culture Collection (ATCC; Manassas,
VA). GES-1, AGS and SW620 cells were maintained and
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(DMEM; Hyclone, Logan, UT) supplemented with 20%
fetal bovine serum (FBS; Hyclone, Logan, UT) and 100 U/
mL penicillin-streptomycin (Sigma, St. Louis, MO).
HepG2 cells were maintained and propagated in RPMI-
1640 (Sigma) supplemented with 10% FBS and 100 U/mL
penicillin-streptomycin. All cells were cultured in
100 mm× 20 mm culture dishes at 37°C in a humidified
atmosphere containing 5% CO2. All experiments were
done using the >90% confluent cultures.
DNA primers and libraries
Random DNA primers and library were designed using
the Integrated DNA Technologies software (IDT, Coralville,
IA), synthesized by standard phosphoramidite chemis-
try with an automated DNA synthesizer (3400 DNA
Synthesizer; Applied Biosystems Inc, Foster City, CA)
and purified by reverse phase High Performance Liquid
Chromatography (RP-HPLC; Shanghai Sangon Bio-
logical Company, Shanghai, China). The purified library
contained a central randomized sequence of 52 nucleo-
tides (nt) flanked by two 18-nt primer hybridization
sites (ATACCAGCTTATTCAATT-52-nt-AGATAGTA
AGTGCAATCT). The forward and reverse primers
used in the PCR performed in the process of cell-
SELEX were separately labeled with fluorescein isothio-
cyanate (FITC) (5′-FITC-ATACCAGCTTATTCAATT-3′)
and biotin (Bio) (5′-Bio-AGATAGTAAGTGCAATCT-3′)
at the 5′ end in order to synthesize double-labeled and
double-stranded DNA molecules.
Procedure of cell-SELEX
AGS cells were used as target cell for positive selections
and GES-1 as negative cell for the counter selections.
The live cell-SELEX was performed and monitored ac-
cording to the protocol reported elsewhere [19]. Briefly,
before the selection, culture cells were washed twice
with washing buffer (4.5 g/L glucose and 5 mM MgCl2
in Dulbecco’s phosphate buffered saline with calcium
chloride and magnesium chloride) (Sigma). 200 pmol of
library or DNA pool was dissolved in 400 μl of binding
buffer (500 nM/L). The binding buffer was prepared by
adding 0.1 mg/ml tRNA (Sigma) and 1 mg/ml of bovine
serum albumin (BSA; Sigma) into washing buffer. The li-
brary or DNA pool was denatured and incubated with
5 × 106 AGS cells at 4°C on rocker for 40 min. After in-
cubation, the cells were washed three times with wash-
ing buffer to remove unbound sequences. The cell-DNA
complex was resuspended in 400 μl binding buffer and
heated at 95°C for 15 min and centrifuged at 14000 rpm
to elute the bound DNAs. The eluted DNAs were then
incubated with 1 × 107 GES-1 cells for counter selection at
4°C on rocker for 40 min. The cells were then centrifuged
at 14000 rpm for 5 min. The supernatant containing thessDNA was recovered and amplified by polymerase chain
reaction (PCR) using FITC- and biotin-labeled primers.
Amplifications were carried out in an Eppendorf PCR ther-
mocycler (Eppendorf GAC 22331, Hamburg, Germany).
The selected sense ssDNA strands were separated from
the biotinylated antisense ssDNA strands by alkaline
denaturation and purified by streptavidin-coated sepharose
beads (Amersham Biosciences). The selected ssDNA was
then dried and resuspended in binding buffer for the next
round of selection. After eight rounds of selections, the
final selected ssDNA pool was PCR-amplified and cloned
into Escherichia coli using the TOTO TA cloning kit
(Invitrogen, Carlsbad, CA). Cloning of the PCR prod-
ucts and sequencing of the selected sense ssDNA were
performed by Shanghai Sangon Biological Company
(Shanghai, China).
Flow cytometric analysis
To assess the enrichment of specific aptamer candidates
and the binding capacity and affinity of the selected
aptamer candidates to AGS cells, culture cells at 90%
confluent were harvested by nonenzymatic cell dissoci-
ation solution (Sigma) and then washed twice with
washing buffer. 5 × 105 cells were incubated with varying
concentrations of FITC-labeled selected ssDNA in
200 μL binding buffer on ice for varied time lengths.
Cells were then washed twice with washing buffer and
suspended in 200 μL washing buffer. The fluorescence
was analyzed by flow cytometry (BD FACS Calibur, BD
Biosciences). The FITC-labeled unselected ssDNA to
AGS and the FITC-labeled selected ssDNA to GES,
HepG2 and SW620 were used as controls. All the exper-
iments were repeated 3 times. The mean fluorescence
intensity of target cells labeled by selected ssDNA was
calculated by subtracting the mean fluorescence inten-
sity of produced by unselected ssDNA.
Imaging of target cells with FITC-labled cy-apt 20
The specificity of the apatamer candidate cy-apt 20 in rec-
ognizing AGS cells was further visualized by fluorescence
imaging. Both HepG2 and SW620 cells were used as con-
trols. Before the imaging, culture cells in flat-bottomed 6-
well plates (Costar, Corning, NY, USA) were washed twice
with washing buffer and then incubated with 400 nM of
FITC-labled cy-apt 20 in 200 μL binding buffer on ice for
40 min. After washing, the stained cells were viewed with
an invert fluorescence microscope (TE2000, Nikon) using
the standard-FITC filter set (excitation at 490 nm and
emission at 520 nm). Pictures of the stained cells were
taken with a DXM1200F digital camera (Nikon).
BALB/c nude mice and xenograft model
Female BALB/c nude mice, 4–6 weeks old, were bred in
the Experimental Animal Center of Nanjing Medical
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ling the animals. The animals were randomly assigned into
three groups, each group contained three mice. The tu-
mors were established by subcutaneous injection of 1 × 106
AGS, SW620, and HepG2 cells in 200 μL PBS into the axil-
lary region of the mice. After tumor imaging, the animals
were euthanized, and tumor tissues were removed. Tumor
tissues were then fixed in 10% buffered formalin, embed-
ded in paraffin, and stained with hematoxylin and eosin for
histopathological examination. The protocol was approved
by the committee on the use of live animals in teaching
and research at Nanjing Medical University.
In vivo imaging of tumors with aptamer cy-apt 20
Mice xenograft model was established as described above.
200 μl of physiological saline containing different concen-
trations of cy-apt 20 labeled with Cy5 was injected via tail
vein when the tumor grown visible for the assessment.
Equivalent Cy5-labled Lib ssDNA was also used as con-
trols. Fluorescence signals were imaged at different time
points after injection of cy5-cy-apt 20 by IVIS Spectrum
Imaging System (Caliper Life Sciences, Hopkinton, MA)
with a 615–665 nm excitation filter and a 695–770 nm
emission filter, respectively. The fluorescence signals of tu-
mors relative to background were also measured and
results were presented as fold changes vs. Background.
Data processing and statistical analysis
The fluorescence was determined with a flow cytometry
by counting 10,000 events per sample. Data were read and
processed by FlowJo software (version 7.6 for Windows,
Tree Star, Ashland, OR). Relative intensity of fluorescence
signals of the imaged tumors were quantified using Image
J software (version 1.47 for Windows, NIH, Bethesda,
MD). Results were presented as mean ± standard error.
Results
Evolution of gastric carcinoma cell-specific aptamer cy-apt
20 by live cell-SELEX
The whole live cell SELEX strategy has been developed
recently for generating aptamers against cancer cells.
The live cell SELEX procedure is simple, fast, straight-
forward, reproducible, and can be done without prior
knowledge of target molecules. We have adopted the live
cell SELEX recently to generate aptamers against gastric
cancer cells. In our study, human gastric carcinoma
AGS cells were used as target cell for positive selections
and human normal gastric epithelial GES-1 cells were
used as negative cell for counter selections. The Live
cell-SELEX procedure and monitoring processes were
done as described elsewhere [19]. After twelve rounds of
selection, the ssDNA sequences with better binding af-
finity to the target cells were being enriched (data not
shown). By cloning, sequencing, and subsequent flowcytometric analyses, thirty potential ssDNA sequences
named cy-apt 01–30 were identified as potential aptamer
candidates specific to AGS cells (data not shown). Among
them, ten sequences had high binding ability to AGS cells,
four sequences had binding rates higher than 60% to AGS
cells (Figure 1A), however, only cy-apt 20 (nucleotide se-
quence: CGACCCGGCACAAACCCAGAACCATATACA
C GATCATTAGTCTCCTGGGCCG) had higher than 70%
of binding rate to AGS cells and less than 30% of binding
affinity to non-gastric cancer cells (Figure 1A and B).
Characterization of aptamer cy-apt 20 in vitro
The binding affinity and capacity of aptamer cy-apt 20
to AGS cells was assessed by flow cytometry. Equivalent
library ssDNA were used as controls at the same condi-
tions for cy-apt 20. The concentration of FITC-cy-apt 20
was first varied from 0 nM to 500 nM, and then the time
length of incubation varied from 0 min to 50 min. The
data showed that the fluorescence intensity of AGS cells
was steadily increased after 40 min of incubation with
increasing concentrations of FITC-cy-apt 20 (Figure 2A
and B) and peaked at the concentration of 400 nM. The
fluorescence intensity of AGS cells were also steadily in-
creased with increasing incubation time length of AGS
cells with FITC-cy-apt 20 and peaked at the time point
of 40 min (Figure 2C and D). Meanwhile, the specificity
of cy-apt 20 in recognizing AGS cells was further visual-
ized by fluorescence imaging. The three kinds of tumor
cells were separately incubated with 400 nM of FITC-
labled cy-apt 20 for 40 min, and then observed with an
invert fluorescence microscope. The result showed that
most of AGS cells were stained by FITC-labled cy-apt 20
(Figure 2Ea), whereas, few living HepG2 (Figure 2Eb)
and SW620 cells (Figure 2Ec) exhibited detectable fluor-
escence. The mean fluorescence intensity of AGS cells
was approximately seven folds of that of HepG2 and
SW620 cells (Figure 2F).
Detection of gastric cancer in vivo using cy-apt 20
The feasibility of using aptamer cy-apt 20 for detecting
gastric cancer in vivo was determined by mouse xenograft
model with IVIS Spectrum Imaging System (Caliper Life
Sciences, Hopkinton, MA). 200 μl of physiological saline
containing 1 nM of cy-apt 20 labeled with Cy5 was
injected via tail vein when the tumor grown visible for the
assessment. Equivalent Cy5-labled Lib ssDNA was also
used as control. Fluorescence signals of the tumors were
imaged with IVIS Spectrum Imaging System at 60 min
after injection (Figure 3A). The fluorescence signals of tu-
mors relative to background were measured using Image J
software (version 1.47 for Windows) and results were pre-
sented as fold changes vs. Background (Figure 3B). Histo-
pathological examination was routinely performed to
confirm the tumor formation when tumor imaging finished
Figure 2 Characterization of aptamer cy-apt 20 in vitro. The specific binding capacity of aptamer cy-apt 20 to gastric carcinoma cells was also
assessed with flow cytometry by varying the concentration of FITC-cy-apt 20 (from 0 nM to 500 nM) for varied time length of incubation (from
0 min to 50 min). Equivalent FITC-Lib ssDNA were used as controls and results were presented as mean ± standard error. (A-B) increased binding
rates were seen with increasing the concentrations of FITC-cy-apt 20 after 40 min of incubation and peaked at 400 nM (arrow notified). (C-D)
increased binding rates were also seen by increasing the incubation time length of AGS cells with 400 nM of FITC-cy-apt 20 (arrow notified) and
peaked at 40 min. (E) The specificity of cy-apt 20 in recognizing AGS cells was further visualized by fluorescence imaging. All the three kinds of
tumor cells were separately incubated with 400 nM of FITC-labled cy-apt 20 for 40 min, and then observed with an invert fluorescence microscope.
(Ea) most of AGS cells were stained by FITC-labled cy-apt 20, whereas, few living HepG2 (Eb) and SW620 (Ec) cells exhibited detectable fluorescence.
(F) The fluorescence signals of tumor cells relative to background were quantified using NIH Image J software and results were presented as fold
changes vs. Background ± standard error. MFI: mean fluorescence intensity. OM: optical microscope; FM: fluorescence microscope.
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Figure 3 Detection of gastric cancer in vivo using cy-apt 20. The
feasibility of using aptamer cy-apt 20 for detecting gastric cancer
in vivo was observed by IVIS Spectrum Imaging System (Caliper Life
Sciences, Hopkinton, MA). AGS cells were subcutaneously injected into
the left axillary regions of BALB/c nude mice and HepG2 and SW620
were transplanted as controls. 200 μl of physiological saline containing
1 nM of cy-apt 20 labeled with Cy5 was injected via tail vein when the
tumor grown visible for the assessment. Equivalent Cy5-labled Lib
ssDNA was also used as control. (A) The top row show visible tumor
formation in the left axillae of the mice (circle notified). The mid-upper
row show histopathological examination of the tumor formation.
Tumor tissues were embedded in paraffin and stained with
hematoxylin and eosin for the examination. The mid-lower row show
there was no fluorescence signal detectable in all tumor sites using
Cy5-labled Lib ssDNA. The bottom row show there were strong
fluorescence signals in AGS tumor site using Cy5-labled cy-apt 20
imaged at 60 min after injection (arrow notified), whereas there was
no fluorescence signal detectable in either tumor site of HepG2 or
SW620. (B) quantification of the signal-to-background ratios of the
tumor imaged using Cy5-labled cy-apt 20. The fluorescence signals
of tumor relative to background were measured using Image J
software and results were presented as fold changes vs. Background ±
standard error.
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cence signal detectable in all tumor sites imaged using
Cy5-labled Lib ssDNA. Strong fluorescence signals were
detected in AGS tumor site imaged using Cy5-labled cy-
apt 20 (Figure 3AB, arrow notified), whereas, there was no
fluorescence signal detectable in either tumor site of
HepG2 or SW620.
Characterization of aptamer cy-apt 20 in vivo
The efficacy of aptamer cy-apt 20 in detecting of gastric
cancer in vivo was further determined by IVIS Spectrum
Imaging System in a dose and time changing manner.
The fluorescence signals of tumors were measured in
the same manner as described above. Measurable fluor-
escence signals were detected at 0.25 nM, then increased
with increasing concentration of cy5-labeled cy-apt 20
(from 0.25 nM to 1.5 nM), and peaked at the concentra-
tion of 1.25 nM (Figure 4AB, arrow notified). Mean-
while, fluorescence signals began to be detectable
10 min after administration of 1 nM cy5-labeled cy-apt
20, then steadily increased by increasing the imaging
interval (from 10 min to 240 min), and peaked at
120 min (Figure 4CD, arrow notified).
Discussion
The live cell-SELEX is proved to be a simple, but effect-
ive, reproducible, and widely applicable approach in gen-
erating high-affinity aptamers without prior knowledge
of target molecules on tumor cells [19-22]. A large num-
ber of useful aptamers generated by this method are
applied in the study of tumor biology, and even in
diagnosis and targeting therapy of cancers [23-31]. The
encouraging results obtained with aptamers combined
Figure 4 Characterization of aptamer cy-apt 20 in vivo. The efficacy of aptamer cy-apt 20 in detecting of gastric cancer in vivo was further
determined by IVIS Spectrum Imaging System in dose and time changing manner. The fluorescence signals of tumors relative to background
were measured using Image J software and results were presented as fold changes vs. Background ± standard error. (A-B) increased fluorescence
signals were detected by increasing the concentration of cy5-labeled cy-apt 20 (from 0.25 nM to 1.5 nM) and peaked at 1.25 nM (arrow notified).
(C-D) increased fluorescence signals were also detected by increasing imaging interval (from 10 min to 240 min) at the concentration of 1 nM of
cy5-labeled cy-apt 20 and peaked at 120 min (arrow notified).
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live cell-SELEX procedure have inspired us to employing
this method to develop gastric cancer specific DNA
aptamers. In our study, human gastric carcinoma AGS
cell was used as target cell for positive selections and hu-
man normal gastric epithelial GES-1 cell was used as
negative cell for counter selections. Through twelve
rounds of successive selections, a pool of ssDNA con-
taining sequences with higher binding affinity to the tar-
get cells has been enriched. By cloning and sequencing,
we identified an ssDNA sequence from the final ssDNA
pool named cy-apt 20 as potential gastric cancer specific
aptamer (Figure 1A). Compared experiments subse-
quently demonstrated that cy-apt 20 had higher than
70% of binding rate to AGS cells and less than 30% of
binding affinity to non-gastric cancer cells (Figure 1B).The data (unpublished yet) indicated that cy-apt 20 may
be a useful tool for detecting and targeting gastric cancer.
In the present study, we were to determine the feasibil-
ity of using cy-apt 20 as a molecular probe for detecting
gastric cancer. The binding affinity and stability of cy-apt
20 in recognition of AGS cells were first assessed by bind-
ing assay in dose and time length changing manners, as a
molecular tool for detecting target cancer cells must pos-
sess tenable binding affinity and stability in addition to
high specificity [1,2,10,12,13]. Equivalent library ssDNA
were used as controls at the same conditions of cy-apt 20.
Flow cytometric analysis showed that cy-apt 20 had higher
than 78% of maximal binding rate to gastric cancer cells,
much higher than that of non-gastric cancer cells. The
fluorescence intensity of AGS cells was steadily increased
after 40 min of incubation with increasing concentrations
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nM (Figure 2A-B). So was the fluorescence intensity of
AGS cells increased by increasing the time length of incu-
bation with 400 nM of FITC-cy-apt 20, peaked at the time
point of 40 min, and lasted for a period of time longer
than 50 min (Figure 3C-D). The results demonstrated that
targeting recognition can be established by using minimal
dose of cy-apt 20 and lasted for a period of time long
enough for detections.
To further ascertain the feasibility of using aptamer
cy-apt 20 for detecting gastric cancer cells in vitro, fluor-
escence imaging was performed in comparison with
non-gastric cancer cells. Because a best biomarker based
diagnosis must be produced in direct, simplified and vi-
sualized ways [1,2,10,12,13]. In the compared examin-
ation, AGS cells were incubated with 400 nM of FITC-
labled cy-apt 20 for 40 min, both human hepatocellular
carcinoma cell HepG2 and colon carcinoma cell SW620
were used as controls. After incubation, the stained cells
were viewed with an invert fluorescence microscope.
The imaging showed that most of the AGS cells were
stained by FITC-labled cy-apt 20 (Figure 2Ea), whereas,
few HepG2 (Figure 2Eb) and SW620 (Figure 2Ec) cells
were stained by FITC-labled cy-apt 20. The fluorescence
intensity of AGS cells was approximately seven folds of
that of HepG2 and SW620 cells (Figure 2F). The results
further indicated that cy-apt 20 may be a useful molecule
tool for detecting and targeting gastric cancer cells.
Next, a mice xenograft model was established to deter-
mine the feasibility of using cy-apt 20 for detecting gastric
cancer in vivo. AGS cells were subcutaneously injected
into the left axillary regions of BALB/c nude mice and
both HepG2 and SW620 were transplanted as controls.
200 μl of physiological saline containing 1 nM of cy-apt
20 labeled with Cy5 was injected via tail vein for in vivo
imaging when the tumor grown visible for the assessment.
Equivalent Cy5-labled Lib ssDNA was also used as control
(Figure 3A). In vivo imaging showed that there was no
fluorescence signal detectable in all tumor sites 60 min
after the injection of Cy5-labled Lib ssDNA. Strong fluor-
escence signals were detected in AGS tumor site after the
injection of Cy5-labled cy-apt 20, whereas, no fluores-
cence signal was detected in either site of HepG2 or
SW620 tumors. The fluorescence signals of AGS tumors
imaged using Cy5-labled cy-apt 20 was approximately five
folds of that of controls (Figure 3B).
The efficacy of using aptamer cy-apt 20 in detecting
gastric cancer in vivo was also assessed in dose and time
length changing manners. Strong fluorescence signals
were detected after injection of 0.25 nM cy5-labeled
cy-apt 20, increased by increasing the concentration of
cy5-labeled cy-apt 20, and peaked at 1.25 nM (arrow no-
tified) (Figure 4A-B). Strong fluorescence signals were
also detected 10 min after injection of 1 nM cy5-labeledcy-apt 20, increased by increasing the imaging interval,
and peaked at 120 min (arrow notified), and lasted for a
period of time longer than 240 min (Figure 4C-D). The
results further demonstrated that aptamer cy-apt 20 pos-
sessed excellent specificity and sensitivity to target cells
with a certain degree of biostability in vivo.
Conclusion
We demonstrated by a series of experiments that cy-apt
20 was an excellent molecular probe with a certain de-
gree of biostability and high specificity and sensitivity for
molecular recognition and targeting therapy of gastric
cancer. Further studies will be necessary to determine
the feasibility of using cy-apt 20 as a vehicle for drug
delivery.
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